This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Tissue regeneration === Collagen scaffolds are used in tissue regeneration, whether in sponges, thin sheets, gels, or fibers. Collagen has favorable properties for tissue regeneration, such as pore structure, permeability, hydrophilicity, and stability in vivo. Collagen scaffolds also support deposition of cells, such as osteoblasts and fibroblasts, and once inserted, facilitate growth to proceed normally.
Three of the hydroxylated and glycosylated propeptides twist into a triple helix (except for its ends), forming procollagen. It is packaged into a transfer vesicle destined for the Golgi apparatus. Modification and secretion: In the Golgi apparatus, the procollagen goes through one last post-translational modification, adding oligosaccharides (not monosaccharides as in step 3). Then it is packaged into a secretory vesicle to be secreted from the cell. Tropocollagen formation: Outside the cell, propeptides at both ends of procollagen are removed by specific enzymes – procollagen N-proteinases and C-proteinases – producing tropocollagen. Defects in this step produce collagenopathies such as dermatosparaxis-type Ehlers–Danlos syndrome. For type III collagen this processing is delayed rather than absent: the C-propeptide is cleaved first, leaving a soluble pN-collagen III intermediate, and the N-propeptide is then removed more slowly by the procollagen N-proteinase ADAMTS-2. Collagen fibril formation: Lysyl oxidase, a copper-dependent enzyme, acts on lysines and hydroxylysines, producing aldehyde groups, which eventually form covalent bonds between tropocollagen molecules. This polymer of tropocollagen is called a collagen fibril.
Bismuth is a brittle metal with a dark, silver-pink hue, often with an iridescent oxide tarnish showing many colors from yellow to blue. The spiral, stair-stepped structure of bismuth crystals is the result of a higher growth rate around the outside edges than on the inside edges. The variations in the thickness of the oxide layer that forms on the surface of the crystal cause different wavelengths of light to interfere upon reflection, thus displaying a rainbow of colors. When burned in oxygen, bismuth burns with a blue flame and its oxide forms yellow fumes. Its toxicity is much lower than that of its neighbors in the periodic table, such as lead and antimony. No other metal is verified to be more naturally diamagnetic than bismuth. Of any metal, it has one of the lowest values of thermal conductivity (after manganese, neptunium, and plutonium) and the highest Hall coefficient. It has the fourth highest electrical resistivity of all the pure metals, only surpassed by gadolinium, manganese and plutonium. When deposited in sufficiently thin layers on a substrate, bismuth is a semiconductor, despite being a post-transition metal. Elemental bismuth is denser in the liquid phase than the solid, a characteristic it shares with germanium, silicon, gallium, plutonium, and water. Bismuth expands 3.32% on solidification, so it was long a component of low-melting typesetting alloys, where it compensated for the contraction of the other alloying components to form almost isostatic bismuth-lead eutectic alloys.
==== United Kingdom ==== Cannabidiol, in an oral-mucosal spray formulation combined with delta-9-tetrahydrocannabinol, is a product available by prescription for the relief of severe spasticity due to multiple sclerosis (where other anti-spasmodics have not been effective) in the United Kingdom. Until 2017, products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA), and could not be marketed without regulatory approval for the medical claims. As of 2018, cannabis oil is legal to possess, buy, and sell in the UK, providing the product does not contain more than 1 milligram of THC and is not advertised as providing a medicinal benefit. Individual police officers and others who are ill-informed of the exact legislature pertaining to cannabidiol, however, may erroneously consider it of dubious legality, reflecting lack of awareness. In January 2019, the UK Food Standards Agency indicated it would regard CBD products, including CBD oil, as a novel food having no history of use before May 1997, and stated that such products must have authorisation and proven safety before being marketed. The deadline for companies with existing products to submit a full and validated novel foods application with the FSA was March 31, 2021; failure to do so before this date would exclude those companies from selling CBD. New products containing CBD after this deadline would require a fully approved application.
the stored elastic strain energy which is released as a crack grows. This is the thermodynamic driving force for fracture. the dissipated energy which includes plastic dissipation and the surface energy (and any other dissipative forces that may be at work). The dissipated energy provides the thermodynamic resistance to fracture. Then the total energy is:
Sources: en.wikipedia.org
==== Neurochemical and neuroendocrine ==== Some neurochemical abnormalities that occur in fibromyalgia also regulate mood, sleep, and energy, thus explaining why mood, sleep, and fatigue problems are commonly co-morbid with fibromyalgia. Serotonin is the most widely studied neurotransmitter in fibromyalgia. It is hypothesized that an imbalance in the serotonergic system may lead to the development of fibromyalgia. There is also some data that suggests altered dopaminergic and noradrenergic signaling in fibromyalgia. Supporting the monoamine related theories is the efficacy of monoaminergic antidepressants in fibromyalgia. Glutamate/creatine ratios within the bilateral ventrolateral prefrontal cortex were found to be significantly higher in fibromyalgia patients than in controls and may disrupt glutamate neurotransmission. Studies on the neuroendocrine system and HPA axis in fibromyalgia have been inconsistent. The depressed function of the HPA axis results in adrenal insufficiency and potentially chronic fatigue.
=== Laboratory tests === Laboratory tests are sometimes used to check for cachexia. Tests that are used include albumin, C-reactive protein, ghrelin, IGF-2, and leptin. Acute phase reactants (IL-6, IL-1b, tumor necrosis factor, IL-8, interferon gamma and serum cytokines are also studied but are not always reliable for predicting cachexia. Laboratory cut-off values are also not the same across different institutions. There is no single lab test that can confirm cachexia or predict whether it will develop.
=== Campaign history === 2012 US Senate election: 2,249 votes (0.07%) 2009 Gubernatorial election: 2,085 votes (0.09%) 2006 US Senate election: 2,490 votes (0.1%) 2002 US Senate election: 2,702 votes (0.13%) 2000 US Senate election: 3,365 votes (0.11%) 1997 Gubernatorial election: 2,800 votes (0.12%) 1994, District 9 Congressional election: 1,490 votes (0.93%)
Within any crystal, there will usually be some defects. To maintain electroneutrality of the crystals, defects that involve loss of a cation will be associated with loss of an anion, i.e. these defects come in pairs. Frenkel defects consist of a cation vacancy paired with a cation interstitial and can be generated anywhere in the bulk of the crystal, occurring most commonly in compounds with a low coordination number and cations that are much smaller than the anions. Schottky defects consist of one vacancy of each type, and are generated at the surfaces of a crystal, occurring most commonly in compounds with a high coordination number and when the anions and cations are of similar size. If the cations have multiple possible oxidation states, then it is possible for cation vacancies to compensate for electron deficiencies on cation sites with higher oxidation numbers, resulting in a non-stoichiometric compound. Another non-stoichiometric possibility is the formation of an F-center, a free electron occupying an anion vacancy. When the compound has three or more ionic components, even more defect types are possible. All of these point defects can be generated via thermal vibrations and have an equilibrium concentration. Because they are energetically costly but entropically beneficial, they occur in greater concentration at higher temperatures. Once generated, these pairs of defects can diffuse mostly independently of one another, by hopping between lattice sites.
Sources: en.wikipedia.org
The plasmon resonance displayed by nanoparticles, gold particles are most often used as an example, can be altered using the interfacial layer. When either anionic or cationic ligands bound to a nanoparticle made of gold for example are increased in length, the wavelength of the plasmon resonance will shift to red. An example of another effect, that has recently been observed by Amendola et al. on small gold nanoparticles, of 10 nm or less, is that dense monolayers that consist of certain specific short chain ligands tend to dampen the surface plasmon resonance effects. Plasmon resonance can be used to analyze the surfactants of the nanoparticle. This principle is based on the so-called Fröhlich condition which states that the refractive index of the surrounding medium of a nanoparticle can be used to tune or alter the frequency of the surface plasmon resonance. The equation that relates both properties is as follows:
The Lowland distillers, who had no opportunity to avoid taxation, complained that untaxed Highland whisky made up more than half the market. The heavy taxation during the Napoleonic Wars gave the illicit trade a large advantage, but their product was also considered better quality, commanding a higher price in the Lowlands. This was due to the method of taxation: malt was subject to tax (at a rate that climbed substantially between the 1790s and 1822). The licensed distillers, therefore, used more raw grain in an effort to reduce their tax bill. The Highland magistrates, themselves members of the landowning classes, had a lenient attitude to unlicensed distillers—all of whom would be tenants in the local area. They understood that the trade supported the rents paid. Imprisoned tenants would not be able to pay any rent. In 1823, Parliament eased restrictions on licensed distilleries with the Excise Act 1823 (4 Geo. 4. c. 94), while at the same time making it harder for the illegal stills to operate. Magistrates found counsel for the Crown appearing in their courts, so forcing the maximum penalties to be applied, with some cases removed to the Court of Exchequer in Edinburgh for tougher sentences. Highland landowners were now happy to remove tenants who were distillers in clearances on their estates. These changes ushered in the modern era of Scotch production: in 1823 2,232,000 gallons of whisky had duty paid on it; in 1824 this increased to 4,350,000 gallons.
FIAU can be synthesized in many ways, with one of the recent ones following a glycosylation strategy typically used in nucleoside chemistry (Figure 2). The synthesis begins with a protected 2-deoxy-2-fluoro-1,3,5-tri-O-benzoyl-D-arabinofuranose to control reactivity at the anomeric carbon. The 5-iodouracil base is converted into a silylated form. Glycosylation is promoted using trimethylsilyl trifluoromethanesulfonate (TMSOTF), which activates the sugar derivative and enables formation of the glycosidic bond between the N1 nitrogen from the pyridine base and the anomeric carbon from the sugar. This procedure simplifies earlier synthetic steps but yields a 1:1 yield of both α and β anomers. Other approaches have demonstrated improved β selectivity (Figure 3). Synthesis of closely related 2-deoxy-2-fluoro-β-D-arabinofuranosesyluracil derivatives employ pre-activated glycosyl donors (such as 1-bromo-2-fluoro sugar intermediates), which resulted in preferential formation of the β anomer in significantly higher proportions. This difference indicates that choice of glycosyl donor has a high influence on the α:β anomer ratio in FIAU, and related nucleoside analogues, synthesis. Although the mentioned strategies involve radiolabelled fluorine-18, the overall synthetic approach is applicable to normal FIAU formation since isotopic substitution does not alter the bonding or reaction pathway.
GLaDOS was built to control the facility and monitor the tests, but researchers found that the computer had villainous tendencies, threatening to kill the entire staff before it was shut down in time. The Aperture researchers constructed a number of "personality cores" that would fit onto GLaDOS to prevent her from turning against them. Despite this, on the day she was officially activated (coincidentally on "Take Your Daughter to Work Day"), she turned against the researchers and killed nearly everyone in the facility with lethal doses of neurotoxin gas. In the games and the comic Lab Rat, one employee Doug Rattmann survived due to his schizophrenia and distrust of GLaDOS. In trying to find a way to defeat GLaDOS, he finds that Chell, one of the human subjects kept in cryogenic storage within Aperture, has a high level of tenacity, and arranges for the events of Portal to occur by moving her to the top of GLaDOS' testing list. GLaDOS remains driven to test human subjects despite the lack of humans.
== Media portrayals == The Edge of Love, 2008 film with Thomas portrayed by Matthew Rhys and his wife, Caitlin, played by Sienna Miller. Set Fire to the Stars, 2014 film with Thomas portrayed by Celyn Jones and John Brinnin by Elijah Wood. Dominion, 2017 film with Thomas played by Rhys Ifans and Caitlin portrayed by Romola Garai.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.